S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
S&P 500   2,659.41 (-0.16%)
DOW   22,653.86 (-0.12%)
QQQ   196.40 (-0.04%)
AAPL   259.43 (-1.16%)
FB   168.83 (+1.98%)
MSFT   163.49 (-1.08%)
GOOGL   1,182.56 (-0.05%)
AMZN   2,011.60 (+0.70%)
CGC   14.50 (+1.12%)
NVDA   259.03 (-3.49%)
BABA   198.00 (+0.79%)
MU   46.54 (+0.37%)
GE   7.03 (-2.77%)
TSLA   545.45 (+5.66%)
AMD   47.56 (+0.08%)
T   30.08 (+2.17%)
ACB   0.80 (+0.00%)
F   4.71 (+3.97%)
NFLX   372.28 (-2.02%)
BAC   22.14 (+3.51%)
GILD   74.67 (-3.94%)
DIS   101.24 (+1.67%)
PRI   88.06 (+1.11%)
Log in

NASDAQ:ATNXAthenex Stock Price, Forecast & News

$8.15
+0.02 (+0.25 %)
(As of 04/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.91
Now: $8.15
$8.65
50-Day Range
$5.71
MA: $10.11
$15.01
52-Week Range
$5.63
Now: $8.15
$21.11
Volume960,700 shs
Average Volume683,388 shs
Market Capitalization$665.26 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Read More
Athenex logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.00 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATNX
CUSIPN/A
Phone716-427-2950

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$101.23 million
Book Value$2.15 per share

Profitability

Net Income$-123,750,000.00
Net Margins-122.25%

Miscellaneous

Employees575
Market Cap$665.26 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive ATNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATNX and its competitors with MarketBeat's FREE daily newsletter.


Athenex (NASDAQ:ATNX) Frequently Asked Questions

How has Athenex's stock been impacted by COVID-19 (Coronavirus)?

Athenex's stock was trading at $9.66 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ATNX stock has decreased by 15.6% and is now trading at $8.15. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Athenex?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Athenex.

When is Athenex's next earnings date?

Athenex is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Athenex.

How were Athenex's earnings last quarter?

Athenex Inc (NASDAQ:ATNX) released its earnings results on Thursday, February, 27th. The company reported ($0.28) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.31) by $0.03. The firm earned $34.36 million during the quarter, compared to the consensus estimate of $12.05 million. Athenex had a negative net margin of 122.25% and a negative return on equity of 86.32%. View Athenex's earnings history.

What price target have analysts set for ATNX?

5 brokerages have issued 1-year price targets for Athenex's shares. Their forecasts range from $20.00 to $31.00. On average, they expect Athenex's stock price to reach $25.80 in the next twelve months. This suggests a possible upside of 216.6% from the stock's current price. View analysts' price targets for Athenex.

Has Athenex been receiving favorable news coverage?

News articles about ATNX stock have been trending very negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Athenex earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAthenex.

Are investors shorting Athenex?

Athenex saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 9,431,000 shares, an increase of 6.8% from the February 27th total of 8,830,000 shares. Based on an average daily trading volume, of 895,200 shares, the days-to-cover ratio is currently 10.5 days. Currently, 15.3% of the shares of the stock are sold short. View Athenex's Current Options Chain.

Who are some of Athenex's key competitors?

What other stocks do shareholders of Athenex own?

Who are Athenex's key executives?

Athenex's management team includes the following people:
  • Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D., Chairman & CEO (Age 59)
  • Mr. Jeffrey M. Yordon, COO & Pres of Athenex Pharmaceutical Division (Age 70)
  • Dr. Rudolf Kwan M.D., M.B., B.S., Exec. VP & Chief Medical Officer (Age 66)
  • Mr. Kam-Chung Leung GBS, LLD, OBE, JP, Strategic & Bus. Advisor (Age 67)
  • Dr. Allen Barnett, Co-Founder & Pres Emeritus

When did Athenex IPO?

(ATNX) raised $72 million in an IPO on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager.

What is Athenex's stock symbol?

Athenex trades on the NASDAQ under the ticker symbol "ATNX."

How do I buy shares of Athenex?

Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Athenex's stock price today?

One share of ATNX stock can currently be purchased for approximately $8.15.

How big of a company is Athenex?

Athenex has a market capitalization of $665.26 million and generates $101.23 million in revenue each year. The company earns $-123,750,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. Athenex employs 575 workers across the globe. View additional information about Athenex.

What is Athenex's official website?

The official website for Athenex is http://www.athenex.com/.

How can I contact Athenex?

Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at 716-427-2950.

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel